Norwegian biorefinery Borregaard saw its shares fall 6% after reporting a fourth-quarter loss. The loss stemmed from NOK 245 million in impairment charges related to investments in bio-based start-ups. Despite record annual earnings and a proposed dividend increase, investors reacted negatively to the quarterly results. This highlights the risks involved in investing in early-stage biotech ventures.

The company's quarterly loss was 0.81 kroner per share, contrasting with earnings of 1.30 kroner a year earlier. The impairment primarily involved a NOK 225 million write-down of Borregaard’s stake in Alginor ASA. The board proposed a dividend of 4.75 kroner per share, up 12%. This reflects a strategic shift impacting investor confidence.

Borregaard's BioSolutions segment performed well, with record annual EBITDA. However, the writedowns overshadowed this positive performance. The company also faces a U.S. anti-dumping investigation. Investors will be watching the annual report for restated figures and the outcome of the anti-dumping case.

This situation underscores the volatile nature of the biotech sector and the importance of diversification. Investors should monitor Borregaard's progress with Alginor and other ventures closely. The impact of the anti-dumping investigation will also be critical to watch for future performance and investor sentiment.